Summary

This article discusses a post hoc analysis of 5 studies of the humanized monoclonal antibody ranibizumab directed against vascular endothelial growth factor-A in the treatment of diabetic macular edema. The analysis focuses on the arterial thromboembolic events associated with ranibizumab that have been reported in controlled clinical trials.